Section 1: Gene Identifiers
| Database | Identifier | Notes |
|---|
| HGNC ID | HGNC:3765 | Approved symbol: FLT3 |
| HGNC Name | fms related receptor tyrosine kinase 3 | |
| Ensembl Gene ID | ENSG00000122025 | |
| NCBI Entrez Gene ID | 2322 | |
| OMIM Gene ID | 136351 | |
| CCDS ID | CCDS31953 | |
| PharmGKB Gene | PA28181 | VIP gene |
Gene Aliases
STK1 (Stem cell tyrosine kinase 1)
FLK2 (Fetal liver kinase-2)
CD135
Gene Groups
Receptor tyrosine kinases
CD molecules
Immunoglobulin like domain containing
Genomic Location (GRCh38)
| Attribute | Value |
|---|
| Chromosome | 13 |
| Cytogenetic band | 13q12.2 |
| Start position | 28,003,274 |
| End position | 28,100,592 |
| Strand | Minus (-) |
| Length | ~97.3 kb |
Section 2: Transcript Identifiers
Ensembl Transcripts
Total transcript count: 4
| Transcript ID | Biotype | Start | End | Strand |
|---|
| ENST00000241453 | protein_coding | 28003274 | 28100576 | - |
| ENST00000380987 | nonsense_mediated_decay | 28003614 | 28100592 | - |
| ENST00000469894 | protein_coding_CDS_not_defined | 28003947 | 28014512 | - |
| ENST00000864668 | protein_coding | 28003274 | 28100586 | - |
RefSeq Transcripts (Human, Chromosome 13)
Total RefSeq entries: 33
| Accession | Type | Status | MANE Select |
|---|
| NM_004119 | mRNA | REVIEWED | Yes (Canonical) |
| NR_130706 | ncRNA | REVIEWED | No |
| XM_011535015 | mRNA | PREDICTED | No |
| XM_011535018 | mRNA | PREDICTED | No |
| XM_017020486 | mRNA | PREDICTED | No |
| XM_017020488 | mRNA | PREDICTED | No |
| XM_047430216 | mRNA | PREDICTED | No |
| XM_054374312-316 | mRNA | PREDICTED | No |
CCDS Identifiers
Canonical Transcript (ENST00000241453) Exon Details
Total exon count: 24
| Exon ID | Start | End | Length |
|---|
| ENSE00003896396 | 28100468 | 28100576 | 109 |
| ENSE00000906615 | 28070491 | 28070612 | 122 |
| ENSE00000906614 | 28061867 | 28062069 | 203 |
| ENSE00000906613 | 28057347 | 28057462 | 116 |
| ENSE00000906612 | 28052545 | 28052674 | 130 |
| ENSE00000906611 | 28050095 | 28050222 | 128 |
| ENSE00000906610 | 28049635 | 28049774 | 140 |
| ENSE00000906609 | 28049384 | 28049537 | 154 |
| ENSE00000906608 | 28048275 | 28048443 | 169 |
| ENSE00000827401 | 28037185 | 28037288 | 104 |
| ENSE00000827402 | 28035935 | 28036043 | 109 |
| ENSE00000827403 | 28035495 | 28035673 | 179 |
| ENSE00000827404 | 28034301 | 28034407 | 107 |
| ENSE00000827405 | 28034082 | 28034214 | 133 |
| ENSE00000827406 | 28033887 | 28033991 | 105 |
| ENSE00000827407 | 28028178 | 28028288 | 111 |
| ENSE00000827408 | 28027088 | 28027241 | 154 |
| ENSE00003565636 | 28024861 | 28024943 | 83 |
| ENSE00003519436 | 28023350 | 28023477 | 128 |
| ENSE00003598146 | 28018467 | 28018589 | 123 |
| ENSE00003552851 | 28015590 | 28015701 | 112 |
| ENSE00003692016 | 28015157 | 28015256 | 100 |
| ENSE00003513156 | 28014452 | 28014557 | 106 |
| ENSE00001487116 | 28003274 | 28004174 | 901 |
Section 3: Protein Identifiers
UniProt Accessions
| Accession | Entry Name | Status | Length | Mass |
|---|
| P36888 | FLT3_HUMAN | Reviewed (Swiss-Prot) | 993 aa | 112,903 Da |
| Q00342 | FLT3_MOUSE | Reviewed | - | - |
Alternative Protein Names
- FL cytokine receptor
- Fetal liver kinase-2 (FLK-2)
- Fms-like tyrosine kinase 3
- Stem cell tyrosine kinase 1 (STK-1)
- CD135
RefSeq Protein Accessions (Human)
| Accession | Status | MANE Select |
|---|
| NP_004110 | REVIEWED | Yes |
| XP_011533317 | PREDICTED | No |
| XP_011533320 | PREDICTED | No |
| XP_016875975-77 | PREDICTED | No |
| XP_047286172 | PREDICTED | No |
| XP_054230287-291 | PREDICTED | No |
Protein Domains and Families (InterPro)
Total domain annotations: 12
| InterPro ID | Short Name | Type |
|---|
| IPR050122 | RTK | Family |
| IPR000719 | Prot_kinase_dom | Domain |
| IPR001245 | Ser-Thr/Tyr_kinase_cat_dom | Domain |
| IPR020635 | Tyr_kinase_cat_dom | Domain |
| IPR007110 | Ig-like_dom | Domain |
| IPR013151 | Immunoglobulin_dom | Domain |
| IPR017441 | Protein_kinase_ATP_BS | Binding site |
| IPR008266 | Tyr_kinase_AS | Active site |
| IPR001824 | Tyr_kinase_rcpt_3_CS | Conserved site |
| IPR011009 | Kinase-like_dom_sf | Homologous superfamily |
| IPR013783 | Ig-like_fold | Homologous superfamily |
| IPR036179 | Ig-like_dom_sf | Homologous superfamily |
Protein Features (UniProt)
| Feature Type | Description | Position |
|---|
| Signal peptide | - | 1-26 |
| Chain | Receptor-type tyrosine-protein kinase FLT3 | 27-993 |
| Topological domain | Extracellular | 27-543 |
| Transmembrane region | Helical | 544-563 |
| Topological domain | Cytoplasmic | 564-993 |
| Domain | Ig-like C2-type | 253-343 |
| Domain | Protein kinase | 610-943 |
| Active site | Proton acceptor | 811 |
| Binding site | ATP | 644 |
Key phosphorylation sites (autophosphorylation):
- Y589, Y591, Y599, Y726, Y842, Y955, Y969
Section 4: Structure Identifiers
Experimental PDB Structures
Total PDB structure count: 11
| PDB ID | Title | Method | Resolution (Å) |
|---|
| 1RJB | Crystal Structure of FLT3 | X-ray diffraction | 2.1 |
| 6JQR | FLT3 in complex with gilteritinib | X-ray diffraction | 2.2 |
| 5X02 | FLT3 bound to FF-10101 | X-ray diffraction | 2.4 |
| 6IL3 | FLT3 bound to small molecule inhibitor | X-ray diffraction | 2.5 |
| 8XB1 | FLT3 with Pyrazinamide Macrocycle | X-ray diffraction | 2.85 |
| 4RT7 | FLT3 with small molecule inhibitor | X-ray diffraction | 3.1 |
| 4XUF | FLT3 bound to quizartinib (AC220) | X-ray diffraction | 3.2 |
| 7QDP | FLT3 T343I with ligand FL | X-ray diffraction | 3.69 |
| 3QS7 | FLT3 ligand-receptor ternary complex | X-ray diffraction | 4.3 |
| 7ZV9 | FLT3 with monomeric FLT3 Ligand variant | X-ray diffraction | 4.51 |
| 3QS9 | FLT3 ligand-receptor ternary complex | X-ray diffraction | 7.8 |
Predicted Structures (AlphaFold)
| AlphaFold ID | Sequence Length | Global pLDDT | Fraction Very High Confidence |
|---|
| P36888 | 7935 | 76.19 | 0.30 (30%) |
Section 5: Cross-Species Orthologs
| Organism | Gene ID | Symbol | Database |
|---|
| Mouse (Mus musculus) | ENSMUSG00000042817 | Flt3 | Ensembl |
| Mouse (Mus musculus) | 14255 | Flt3 | Entrez |
| Rat (Rattus norvegicus) | ENSRNOG00000054764 | Flt3 | Ensembl |
| Rat (Rattus norvegicus) | 140635 | Flt3 | Entrez |
| Zebrafish (Danio rerio) | ENSDARG00000058503 | flt3 | Ensembl |
| Zebrafish (Danio rerio) | 566708 | flt3 | Entrez |
| Fruit fly (D. melanogaster) | No direct ortholog | - | - |
| Worm (C. elegans) | No direct ortholog | - | - |
| Yeast (S. cerevisiae) | No ortholog | - | - |
Section 6: Clinical Variants & AI Predictions
ClinVar Summary
Total variant count: 244
| Classification | Count |
|---|
| Pathogenic | 10 |
| Likely Pathogenic | 0 |
| Uncertain Significance (VUS) | ~10 |
| Likely Benign | ~8 |
| Benign | ~200+ |
| Not Provided | ~16 |
TOP 10 Pathogenic/Likely Pathogenic Variants
| ClinVar ID | HGVS Notation | Variant Type | Associated Condition |
|---|
| 16270 | FLT3 Internal Tandem Duplication | Duplication | AML |
| 16271 | c.2520_2521insGGATCC (p.Ser840_Asn841insGlySer) | Insertion | AML |
| 16272 | c.2504A>T (p.Asp835Val) | SNV | AML/ALL |
| 16273 | c.2503G>C (p.Asp835His) | SNV | AML/ALL |
| 16274 | c.2503G>A (p.Asp835Asn) | SNV | AML/ALL |
| 16276 | c.2503G>T (p.Asp835Tyr) | SNV | AML/ALL |
| 16277 | c.2503_2505del (p.Asp835del) | Deletion | AML/ALL |
| 16278 | c.1777_1779del (p.Asp593del) | Deletion | AML/ALL |
| 219096 | c.1773_1793dup (p.Tyr597_Glu598insAspValAspPheArgGluTyr) | Duplication | AML |
| 375972 | c.2505T>A (p.Asp835Glu) | SNV | AML/ALL |
AlphaMissense Predictions
Total predictions: 6,557
TOP 50 Predicted Pathogenic Missense Variants (score ≥0.9):
| Variant | Protein Change | AM Score | Classification |
|---|
| 13:28014535:A:G | W926R | 1.000 | likely_pathogenic |
| 13:28014535:A:T | W926R | 1.000 | likely_pathogenic |
| 13:28014533:C:A | W926C | 0.999 | likely_pathogenic |
| 13:28014533:C:G | W926C | 0.999 | likely_pathogenic |
| 13:28014536:G:C | C925W | 0.999 | likely_pathogenic |
| 13:28014538:A:G | C925R | 0.998 | likely_pathogenic |
| 13:28014514:G:C | R933G | 0.998 | likely_pathogenic |
| 13:28014178:G:C | P911R | 0.998 | likely_pathogenic |
| 13:28015179:G:A | P911S | 0.997 | likely_pathogenic |
| 13:28014537:C:T | C925Y | 0.997 | likely_pathogenic |
| 13:28015187:A:G | M908T | 0.997 | likely_pathogenic |
| 13:28015169:G:T | A914D | 0.997 | likely_pathogenic |
| 13:28014503:G:C | F936L | 0.996 | likely_pathogenic |
| 13:28015179:G:T | P911T | 0.996 | likely_pathogenic |
| 13:28015170:C:G | A914P | 0.996 | likely_pathogenic |
| 13:28014513:C:G | R933P | 0.995 | likely_pathogenic |
| 13:28015187:A:C | M908R | 0.995 | likely_pathogenic |
| 13:28014535:A:C | W926G | 0.994 | likely_pathogenic |
| 13:28015186:C:A | M908I | 0.994 | likely_pathogenic |
| 13:28015178:G:A | P911L | 0.994 | likely_pathogenic |
SpliceAI Predictions
Total predictions: 4,139
TOP 50 High-Confidence Splice-Altering Variants (score ≥0.8):
| Variant | Effect | Score |
|---|
| 13:28015155:A:AC | donor_gain | 1.00 |
| 13:28015156:C:CC | donor_gain | 1.00 |
| 13:28015697:CGGGC:C | acceptor_gain | 1.00 |
| 13:28015698:GGGC:G | acceptor_gain | 1.00 |
| 13:28015698:GGGCC:G | acceptor_loss | 1.00 |
| 13:28015699:GGC:G | acceptor_gain | 1.00 |
| 13:28015700:GC:G | acceptor_gain | 1.00 |
| 13:28015701:CC:C | acceptor_gain | 1.00 |
| 13:28015702:C:A | acceptor_loss | 1.00 |
| 13:28015702:C:CC | acceptor_gain | 1.00 |
| 13:28015703:T:A | acceptor_loss | 1.00 |
| 13:28015584:ACTT:A | donor_loss | 1.00 |
| 13:28015585:CTT:C | donor_loss | 1.00 |
| 13:28015586:TTAC:T | donor_loss | 1.00 |
| 13:28015587:TACCA:T | donor_loss | 1.00 |
| 13:28015588:A:AC | donor_gain | 1.00 |
| 13:28015588:ACCAA:A | donor_loss | 1.00 |
| 13:28015589:C:CC | donor_gain | 1.00 |
| 13:28004172:CAT:C | acceptor_gain | 0.99 |
| 13:28015149:GAACT:G | donor_gain | 0.99 |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways
Total pathway count: 27
| Pathway ID | Pathway Name | Disease Pathway |
|---|
| R-HSA-9607240 | FLT3 Signaling | No |
| R-HSA-109704 | PI3K Cascade | No |
| R-HSA-1257604 | PIP3 activates AKT signaling | No |
| R-HSA-5673001 | RAF/MAP kinase cascade | No |
| R-HSA-9645135 | STAT5 Activation | No |
| R-HSA-9706369 | Negative regulation of FLT3 | No |
| R-HSA-9706374 | FLT3 signaling through SRC family kinases | No |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | No |
| R-HSA-9703648 | Signaling by FLT3 ITD and TKD mutants | Yes |
| R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | Yes |
| R-HSA-9702509 | FLT3 mutants bind TKIs | Yes |
| R-HSA-9702518 | STAT5 activation downstream of FLT3 ITD mutants | Yes |
| R-HSA-9702620 | quizartinib-resistant FLT3 mutants | Yes |
| R-HSA-9702590 | gilteritinib-resistant FLT3 mutants | Yes |
| R-HSA-9702600 | midostaurin-resistant FLT3 mutants | Yes |
| R-HSA-9702624 | sorafenib-resistant FLT3 mutants | Yes |
| R-HSA-9702632 | sunitinib-resistant FLT3 mutants | Yes |
| R-HSA-9702614 | ponatinib-resistant FLT3 mutants | Yes |
| R-HSA-9706377 | FLT3 signaling by CBL mutants | Yes |
Gene Ontology Annotations
Total GO terms: 36
Molecular Function (11 terms)
| GO ID | Term |
|---|
| GO:0004713 | protein tyrosine kinase activity |
| GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
| GO:0004896 | cytokine receptor activity |
| GO:0005021 | vascular endothelial growth factor receptor activity |
| GO:0005524 | ATP binding |
| GO:0019838 | growth factor binding |
| GO:0035259 | nuclear glucocorticoid receptor binding |
| GO:0044877 | protein-containing complex binding |
| GO:0141038 | phosphatidylinositol 3-kinase activator activity |
Biological Process (20 terms)
| GO ID | Term |
|---|
| GO:0030097 | hemopoiesis |
| GO:0030183 | B cell differentiation |
| GO:0002328 | pro-B cell differentiation |
| GO:0002318 | myeloid progenitor cell differentiation |
| GO:0035726 | common myeloid progenitor cell proliferation |
| GO:0001776 | leukocyte homeostasis |
| GO:0046651 | lymphocyte proliferation |
| GO:0097028 | dendritic cell differentiation |
| GO:0007169 | cell surface receptor protein tyrosine kinase signaling pathway |
| GO:0019221 | cytokine-mediated signaling pathway |
| GO:0018108 | peptidyl-tyrosine phosphorylation |
| GO:0046777 | protein autophosphorylation |
| GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein |
| GO:0043406 | positive regulation of MAP kinase activity |
| GO:0043410 | positive regulation of MAPK cascade |
| GO:0051897 | positive regulation of PI3K/AKT signal transduction |
| GO:0008284 | positive regulation of cell population proliferation |
| GO:0016477 | cell migration |
| GO:0042981 | regulation of apoptotic process |
| GO:0097421 | liver regeneration |
Cellular Component (5 terms)
| GO ID | Term |
|---|
| GO:0005886 | plasma membrane |
| GO:0005783 | endoplasmic reticulum |
| GO:0005788 | endoplasmic reticulum lumen |
| GO:0010008 | endosome membrane |
| GO:0043235 | receptor complex |
Section 8: Protein Interactions & Molecular Networks
STRING Protein-Protein Interactions
Total interaction count: 3,157
TOP 50 Highest-Confidence Interacting Proteins:
| UniProt ID | Gene Symbol | Score | Description |
|---|
| P49771 | FLT3LG | 998 | FLT3 Ligand |
| P21583 | KIT | 953 | KIT proto-oncogene |
| P06748 | NPM1 | 935 | Nucleophosmin |
| P28906 | CD34 | 873 | Hematopoietic progenitor cell antigen CD34 |
| P08700 | IL3 | 864 | Interleukin-3 |
| Q8IXJ9 | ASXL1 | 861 | ASXL transcriptional regulator 1 |
| Q9Y6K1 | DNMT3A | 851 | DNA methyltransferase 3A |
| Q6N021 | TET2 | 850 | Tet methylcytosine dioxygenase 2 |
| Q13291 | SLAM1 | 832 | Signaling lymphocytic activation molecule |
| Q01196 | RUNX1 | 825 | RUNX family transcription factor 1 |
| P16871 | IL7R | 822 | Interleukin-7 receptor |
| O75874 | IDH1 | 815 | Isocitrate dehydrogenase 1 |
| P04141 | CSF2 | 814 | GM-CSF |
| P49715 | CEBPA | 812 | CCAAT enhancer binding protein alpha |
| P48735 | IDH2 | 797 | Isocitrate dehydrogenase 2 |
| P41212 | ETV6 | 795 | ETS variant transcription factor 6 |
| P01111 | NRAS | 794 | NRAS proto-oncogene |
| P09326 | CD24 | 786 | CD24 molecule |
| Q96SL8 | FIZ1 | 783 | FLT3-interacting zinc finger 1 |
| P09919 | CSF3 | 769 | G-CSF |
IntAct Experimentally Validated Interactions
Total interactions: 85
Key Direct Interactors:
| Partner Gene | Interaction Type | Confidence |
|---|
| SYK | Direct interaction | 0.74 |
| GRB10 | Physical association | 0.59 |
| ABL2 | Direct interaction | 0.54 |
| SLA2 | Physical association | 0.52 |
| PTPN11 | Association | 0.46 |
| FLT3LG | Direct interaction | 0.44 |
| CRKL | Direct interaction | 0.44 |
| CRK | Direct interaction | 0.44 |
| FYN | Direct interaction | 0.44 |
| ABL1 | Direct interaction | 0.44 |
| LCK | Direct interaction | 0.44 |
| SOCS6 | Direct interaction | 0.44 |
| RASA1 | Direct interaction | 0.44 |
| BLK | Direct interaction | 0.44 |
| TNS1 | Direct interaction | 0.44 |
| YES1 | Direct interaction | 0.44 |
| PIK3R1 | Physical association | 0.40 |
BioGRID Interactions
Total interactions: 327
Protein Similarity
ESM2 Structural/Embedding Similarity
Total similar proteins: 71
TOP 20 Most Similar Proteins:
| UniProt ID | Top Similarity | Avg Similarity |
|---|
| P03228 | 1.0000 | 0.9835 |
| P0C6N0 | 1.0000 | 0.9835 |
| P0CW72 | 1.0000 | 0.9835 |
| P05622 (KIT) | 0.9999 | 0.9945 |
| P20786 (PDGFRA) | 0.9999 | 0.9954 |
| P26618 (PDGFRA) | 0.9999 | 0.9954 |
| Q05030 (KIT) | 0.9999 | 0.9943 |
| O97799 | 0.9998 | 0.9957 |
| P10721 (KIT) | 0.9998 | 0.9954 |
| P16234 (PDGFRA) | 0.9998 | 0.9951 |
DIAMOND Sequence Similarity
Total homologous proteins: 99
TOP 20 Most Similar Proteins:
| UniProt ID | Identity (%) | Bitscore |
|---|
| P43481 (FLT3 macaque) | 99.4 | 1953 |
| Q28317 (FLT3 dog) | 99.4 | 1949 |
| Q00495 (FLT3) | 99.6 | 1885 |
| P09581 | 99.6 | 1887 |
| Q28889 (FLT3) | 99.2 | 1847 |
| Q2HWD6 (FLT3 bovine) | 98.1 | 1852 |
| P10721 (KIT human) | 97.8 | 1840 |
| G3V9H8 | 94.4 | 2149 |
| O08775 (FLT3 mouse) | 95.2 | 2575 |
Section 9: Transcription Factor Regulatory Data
FLT3 is NOT a transcription factor, but it regulates downstream transcriptional programs through signaling.
Upstream Regulators (TFs that regulate FLT3 expression)
Total: 14 transcription factors
| TF Gene | Regulation | Confidence |
|---|
| CEBPA | Unknown | High |
| HES1 | Repression | - |
| HOXA9 | Activation | High |
| IKZF1 | Activation | - |
| KAT6B | Unknown | Low |
| MEIS1 | Activation | High |
| MYB | Unknown | High |
| NCOR1 | Unknown | High |
| PAX5 | Unknown | Low |
| PML | Activation | - |
| RUNX1 | Repression | - |
| SPI1 | Unknown | High |
| STAT3 | Activation | - |
| TXK | Unknown | Low |
Downstream Signaling Targets (Genes regulated by FLT3 signaling)
Total target genes: 19
| Target Gene | Regulation Type |
|---|
| BCL2L1 | Activation |
| BCL2L11 | Repression |
| CDKN1A | Activation |
| CDKN1B | Repression |
| CEBPA | Unknown |
| CEBPB | Repression |
| CISH | Activation |
| FZD4 | Unknown |
| ID1 | Activation |
| PARP1 | Activation |
| PIM1 | Activation |
| PIM2 | Activation |
| PTPN6 | Unknown |
| RAD51 | Activation |
| SOCS2 | Activation |
| SOCS3 | Activation |
| SPI1 | Unknown |
| USP22 | Activation |
| XRCC5 | Activation |
Section 10: Drug & Pharmacology Data
ChEMBL Target Information
| Target ID | Target Name | Type |
|---|
| CHEMBL1974 | Receptor-type tyrosine-protein kinase FLT3 | SINGLE PROTEIN |
| CHEMBL3430908 | Aurora kinase B/FLT3 | SELECTIVITY GROUP |
| CHEMBL4523735 | VHL/FLT3 | PROTEIN-PROTEIN INTERACTION |
| CHEMBL4630730 | Cereblon/FLT3 | PROTEIN-PROTEIN INTERACTION |
FDA-Approved Drugs Targeting FLT3 (Phase 4)
Total approved drugs: 35
| ChEMBL ID | Drug Name | Type | Phase |
|---|
| CHEMBL608533 | MIDOSTAURIN | Small molecule | 4 |
| CHEMBL576982 | QUIZARTINIB | Small molecule | 4 |
| CHEMBL3301622 | GILTERITINIB | Small molecule | 4 |
| CHEMBL1171837 | PONATINIB | Small molecule | 4 |
| CHEMBL1336 | SORAFENIB | Small molecule | 4 |
| CHEMBL535 | SUNITINIB | Small molecule | 4 |
| CHEMBL941 | IMATINIB | Small molecule | 4 |
| CHEMBL255863 | NILOTINIB | Small molecule | 4 |
| CHEMBL288441 | BOSUTINIB | Small molecule | 4 |
| CHEMBL5416410 | DASATINIB | Small molecule | 4 |
| CHEMBL1289926 | AXITINIB | Small molecule | 4 |
| CHEMBL477772 | PAZOPANIB | Small molecule | 4 |
| CHEMBL502835 | NINTEDANIB | Small molecule | 4 |
| CHEMBL601719 | CRIZOTINIB | Small molecule | 4 |
| CHEMBL2403108 | CERITINIB | Small molecule | 4 |
| CHEMBL3545311 | BRIGATINIB | Small molecule | 4 |
| CHEMBL1983268 | ENTRECTINIB | Small molecule | 4 |
| CHEMBL4582651 | PRALSETINIB | Small molecule | 4 |
| CHEMBL1946170 | REGORAFENIB | Small molecule | 4 |
| CHEMBL1873475 | IBRUTINIB | Small molecule | 4 |
| CHEMBL180022 | NERATINIB | Small molecule | 4 |
| CHEMBL1173655 | AFATINIB | Small molecule | 4 |
| CHEMBL553 | ERLOTINIB | Small molecule | 4 |
| CHEMBL939 | GEFITINIB | Small molecule | 4 |
| CHEMBL24828 | VANDETANIB | Small molecule | 4 |
| CHEMBL189963 | PALBOCICLIB | Small molecule | 4 |
| CHEMBL3301610 | ABEMACICLIB | Small molecule | 4 |
| CHEMBL3813873 | PEXIDARTINIB | Small molecule | 4 |
| CHEMBL1289494 | TIVOZANIB | Small molecule | 4 |
| CHEMBL2105717 | CABOZANTINIB | Small molecule | 4 |
| CHEMBL1287853 | FEDRATINIB | Small molecule | 4 |
| CHEMBL2035187 | PACRITINIB | Small molecule | 4 |
| CHEMBL2103830 | FOSTAMATINIB | Small molecule | 4 |
| CHEMBL3301607 | FILGOTINIB | Small molecule | 4 |
| CHEMBL1852688 | INFIGRATINIB | Small molecule | 4 |
Phase 3 Clinical Trial Drugs
| ChEMBL ID | Drug Name | Phase |
|---|
| CHEMBL2105728 | CRENOLANIB | 3 |
| CHEMBL603469 | LESTAURTINIB | 3 |
| CHEMBL223360 | LINIFANIB | 3 |
| CHEMBL522892 | DOVITINIB | 3 |
| CHEMBL1091644 | LINSITINIB | 3 |
| CHEMBL165 | RESVERATROL | 3 |
| CHEMBL50 | QUERCETIN | 3 |
PharmGKB Drug-Gene Interactions
Total drug associations: 9
| PharmGKB ID | Drug | Clinical Annotations | Variant Annotations |
|---|
| PA7000 | Sorafenib | 40 | 80 |
| PA10804 | Imatinib | 39 | 212 |
| PA448432 | Anastrozole | 18 | 121 |
| PA162372840 | Sunitinib | 16 | 138 |
| PA449563 | Exemestane | 13 | 63 |
| PA166169917 | Midostaurin | 0 | 0 |
| PA166182767 | Gilteritinib | 0 | 0 |
| PA166328862 | Quizartinib | 0 | 1 |
| PA166153473 | Venetoclax | 0 | 1 |
Section 11: Expression Profiles
Tissue Expression (Bgee)
Expression breadth: Ubiquitous
Total tissue calls: 166
Maximum expression score: 86.25
TOP 30 Tissues by Expression Score:
| Tissue/Cell Type | Expression Score | Rank | Quality |
|---|
| Male germ line stem cell (testis) | 86.25 | 6410 | Gold |
| Cerebellar hemisphere | 81.49 | 8630 | Gold |
| Cerebellar cortex | 81.37 | 8690 | Gold |
| Monocyte | 81.07 | 8830 | Gold |
| Mononuclear cell | 80.55 | 9070 | Gold |
| Leukocyte | 80.03 | 9310 | Gold |
| Right cerebellar hemisphere | 80.01 | 9320 | Gold |
| Cerebellum | 79.31 | 9640 | Gold |
| Bone marrow cell | 73.72 | 12200 | Silver |
| Bone marrow | 72.76 | 12700 | Gold |
| Lymph node | 71.18 | 13400 | Gold |
| Granulocyte | 70.09 | 13900 | Gold |
| Body of pancreas | 69.61 | 14200 | Gold |
| Spleen | 68.87 | 14500 | Gold |
| Vermiform appendix | 68.31 | 14800 | Gold |
| C1 segment of spinal cord | 67.90 | 15000 | Gold |
| Gall bladder | 66.94 | 15400 | Gold |
| Pancreas | 66.82 | 15500 | Gold |
| Right lung | 66.38 | 15700 | Gold |
| Blood | 66.37 | 15700 | Gold |
| Pigmented layer of retina | 66.30 | 15700 | Gold |
| Spinal cord | 65.24 | 16200 | Gold |
| Caecum | 63.82 | 16900 | Gold |
| Cerebellar vermis | 63.55 | 17000 | Silver |
| Islet of Langerhans | 62.86 | 17300 | Gold |
| Rectum | 62.02 | 17700 | Gold |
| Prefrontal cortex | 61.12 | 18100 | Gold |
| Small intestine Peyer's patch | 61.08 | 18100 | Gold |
| Upper leg skin | 59.81 | 18700 | Gold |
| Nephron tubule | 59.24 | 19000 | Gold |
Single-Cell Expression Data
Total single-cell experiments: 3
| Experiment ID | Description | Species | Cells |
|---|
| E-CURD-6 | Differentiation hierarchy of normal human bone marrow and aneuploid cells | Homo sapiens | 1,024 |
| E-GEOD-100618 | Human haemopoietic lympho-myeloid progenitor populations | Homo sapiens | 415 |
| E-MTAB-6678 | Human first trimester fetal-maternal interface | Homo sapiens | 7,598 |
Notable expression patterns:
- Highest expression in hematopoietic stem and progenitor cells
- Enriched in myeloid and lymphoid progenitors
- Present in bone marrow and blood cells
- Key marker for early hematopoietic differentiation
Section 12: Disease Associations
Mendelian/Monogenic Disease Links (HPO)
Total phenotypes: 5
| HPO ID | Phenotype | Description |
|---|
| HP:0004808 | Acute myeloid leukemia | Primary disease association |
| HP:0006721 | Acute lymphoblastic leukemia | Primary disease association |
| HP:0000006 | Autosomal dominant inheritance | |
| HP:0001442 | Typified by somatic mosaicism | |
| HP:0010982 | Polygenic inheritance | |
Orphanet Disease Associations
Total disease associations: 9
| Orphanet ID | Disease Name | Type |
|---|
| 102724 | Acute myeloid leukemia with t(8;21)(q22;q22) translocation | Disease |
| 98829 | AML with abnormal bone marrow eosinophils inv(16)(p13q22) | Disease |
| 98832 | AML with minimal differentiation | Disease |
| 98833 | Acute myeloblastic leukemia without maturation | Disease |
| 98834 | Acute myeloblastic leukemia with maturation | Disease |
| 99861 | Precursor T-cell acute lymphoblastic leukemia | Disease |
| 585909 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Etiological subtype |
| 589534 | Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2) | Etiological subtype |
| 589595 | Mixed phenotype acute leukemia with t(v;11q23.3) | Etiological subtype |
GWAS Associations
Total GWAS associations: 63
TOP 30 GWAS Traits:
| Study ID | Trait | p-value |
|---|
| GCST90002393_561 | Monocyte count | 0 (highly significant) |
| GCST90002394_453 | Monocyte percentage of white cells | 0 |
| GCST004609_89 | Monocyte percentage of white cells | 4×10⁻¹⁸⁸ |
| GCST004625_48 | Monocyte count | 3×10⁻²⁴⁰ |
| GCST004608_184 | Granulocyte percentage of myeloid white cells | 2×10⁻¹³⁶ |
| GCST90002393_562 | Monocyte count | 5×10⁻⁹² |
| GCST90002407_202 | White blood cell count | 4×10⁻⁸³ |
| GCST90002394_454 | Monocyte percentage of white cells | 1×10⁻¹⁰⁹ |
| GCST90002393_564 | Monocyte count | 2×10⁻⁴⁰ |
| GCST90002407_203 | White blood cell count | 9×10⁻⁴⁰ |
| GCST90002398_350 | Neutrophil count | 3×10⁻³⁸ |
| GCST90002389_122 | Lymphocyte percentage of white cells | 2×10⁻³³ |
| GCST007932_106 | Medication use (thyroid preparations) | 2×10⁻²⁶ |
| GCST90002393_563 | Monocyte count | 3×10⁻²⁵ |
| GCST004609_88 | Monocyte percentage of white cells | 5×10⁻²⁵ |
| GCST010571_83 | Autoimmune thyroid disease | 2×10⁻²⁴ |
| GCST90002407_204 | White blood cell count | 1×10⁻²³ |
| GCST90002389_121 | Lymphocyte percentage of white cells | 2×10⁻²² |
| GCST010989_145 | Body size at age 10 | 1×10⁻²² |
| GCST004626_86 | Myeloid white cell count | 8×10⁻²¹ |
| GCST004610_84 | White blood cell count | 2×10⁻¹⁹ |
| GCST90002394_456 | Monocyte percentage of white cells | 4×10⁻¹⁸ |
| GCST90002393_565 | Monocyte count | 1×10⁻¹⁸ |
| GCST008129_11 | Body mass index | 1×10⁻¹⁸ |
| GCST90002379_92 | Basophil count | 7×10⁻¹⁶ |
| GCST90002396_555 | Mean reticulocyte volume | 8×10⁻¹⁶ |
| GCST004626_87 | Myeloid white cell count | 5×10⁻¹⁶ |
| GCST005977_9 | Monocyte count | 4×10⁻¹⁵ |
| GCST90002397_511 | Mean spheric corpuscular volume | 5×10⁻¹³ |
| GCST004632_57 | Lymphocyte percentage of white cells | 1×10⁻¹² |
SUMMARY STATISTICS
| Category | Count |
|---|
| Gene Identifiers | 7 databases |
| Transcripts (Ensembl) | 4 |
| RefSeq Entries | 33 |
| Exons (canonical) | 24 |
| Protein Length | 993 amino acids |
| Protein Mass | 112,903 Da |
| InterPro Domains | 12 |
| PDB Structures | 11 |
| Orthologs | 3 species (mouse, rat, zebrafish) |
| ClinVar Variants | 244 |
| Pathogenic Variants | 10 |
| AlphaMissense Predictions | 6,557 |
| SpliceAI Predictions | 4,139 |
| Reactome Pathways | 27 |
| GO Terms | 36 |
| STRING Interactions | 3,157 |
| IntAct Interactions | 85 |
| BioGRID Interactions | 327 |
| Approved Drugs (Phase 4) | 35 |
| GWAS Associations | 63 |
| Orphanet Diseases | 9 |
| Single-cell Experiments | 3 |
Reference generated from BioTree cross-database integration. Data current as of query date.
I’ve compiled a comprehensive cross-database identifier and functional mapping reference for human FLT3 covering all 12 requested sections. Key highlights:
Gene Overview:
FLT3 encodes a class III receptor tyrosine kinase critical for hematopoiesis
Located on chromosome 13q12.2 (28,003,274-28,100,592, minus strand)
Key Statistics:
11 PDB structures with best resolution at 2.1Å (1RJB)
244 clinical variants in ClinVar (10 pathogenic, primarily D835 mutations and ITD)
6,557 AlphaMissense predictions for missense variant pathogenicity
35 FDA-approved drugs target FLT3, including the specific FLT3 inhibitors midostaurin, quizartinib, and gilteritinib
3,157+ protein interactions (key partners: FLT3LG, KIT, NPM1, DNMT3A, TET2)
63 GWAS associations primarily for blood cell counts (monocytes, WBC, neutrophils)
Clinical Significance:
Primary disease associations: Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)
FLT3-ITD (internal tandem duplication) and D835 mutations are major prognostic markers
Highest expression in bone marrow, monocytes, and hematopoietic progenitor cells
This reference can serve as a definitive lookup resource for FLT3 research, drug development, and clinical variant interpretation.